• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The MADIT-II trial: Prophylactic defibrillators improve survival in patients with myocardial infarction and left ventricular dysfunction

bys25qthea
June 3, 2013
in General Medicine Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: CC/L. academia

1. This trial found a 31% reduction in risk of death associated with implantation of a defibrillator compared to conventional therapy.

2. Rates of hospitalization with heart failure were somewhat higher in the defibrillator group, though this did not reach significance.

Study Rundown: Prophylactic implantation of a defibrillator may improve survival in patients with previous myocardial infarction and left ventricular dysfunction. The results of this trial indicate that an implantable defibrillator may significantly improve outcomes along with appropriate drug therapy. Of concern was the higher rate of hospitalization with heart failure in the defibrillator group. Further investigations, including electrophysiologic testing, as inclusion criteria may help to determine the specific groups for whom implantation of a defibrillator will be most beneficial with minimal risk.

In sum, implantation of a defibrillator should be considered in patients with myocardial infarction and reduced ejection fraction as a prophylactic measure for sudden cardiac death.

Please click to read study in NEJM

RELATED REPORTS

Coronary CT-angiography-guided management improves outcomes in patients with stable chest pain

Spironolactone ineffective for patients with preserved ejection fraction after myocardial infarction

Catheter-guided aortic valve replacement and angioplasty has favorable outcomes compared to surgical intervention

In Depth [randomized controlled study]: Published in NEJM in 2002, the MADIT-II trial assessed the survival benefit of prophylactic defibrillator implantation in patients with previous myocardial infarction and an ejection fraction of 0.30 or less. A total of 1,232 patients were assigned to receive an implantable defibrillator or to conventional medical therapy in a 3:2 ratio. After an average follow-up of 20 months, the trial found a significant 31% reduction in risk of death in the defibrillator group compared to the conventional therapy group. Subgroup analyses did not reveal any differences in this effect based on a number of factors, including age, gender, ejection fraction, and QRS interval. Serious complications associated with defibrillator therapy were uncommon, but of note was a slightly higher rate of hospitalization with heart failure in the defibrillator group compared to conventional therapy.

By Adrienne Cheung, Andrew Cheung, M.D.

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

Tags: defibrillatorsmadit-iimyocardial infarction
Previous Post

[Policy Statement] New guidelines for pediatric acute otitis media released

Next Post

Fibrosis linked with mortality in nonischemic dilated cardiomyopathy patients

RelatedReports

Physician visual assessment of coronary stenosis severity overestimates quantitative coronary angiography
Cardiology

Coronary CT-angiography-guided management improves outcomes in patients with stable chest pain

March 12, 2025
Cardiology

Spironolactone ineffective for patients with preserved ejection fraction after myocardial infarction

March 4, 2025
Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease
Cardiology

Catheter-guided aortic valve replacement and angioplasty has favorable outcomes compared to surgical intervention

February 11, 2025
Cardiology

Beta-blocker interruption not noninferior to continuation following myocardial infarction

November 21, 2024
Next Post
Fibrosis linked with mortality in nonischemic dilated cardiomyopathy patients

Fibrosis linked with mortality in nonischemic dilated cardiomyopathy patients

Regional wall thinning in CAD may be reversible

Regional wall thinning in CAD may be reversible

The RE-COVER trial: Dabigatran non-inferior to warfarin in treating acute venous thromboembolism [Classics Series]

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer
  • Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients
  • Rectoscopy alone may be sufficient to evaluate for remission of ulcerative colitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.